BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28514722)

  • 1. The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
    Li M; Song X; Zhu J; Fu A; Li J; Chen T
    Clin Neurol Neurosurg; 2017 Aug; 159():6-12. PubMed ID: 28514722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
    Salmaggi A; Duri S; Silvani A; Gaviani P; Milanesi I; Casali C; Di Meco F
    Neurol Sci; 2011 Nov; 32 Suppl 2():S241-5. PubMed ID: 21983866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
    Liu Y; Strawderman MS; Warren KT; Richardson M; Serventi JN; Mohile NA; Milano MT; Walter KA
    Anticancer Res; 2020 Oct; 40(10):5801-5806. PubMed ID: 32988908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
    Dixit S; Hingorani M; Achawal S; Scott I
    Br J Neurosurg; 2011 Aug; 25(4):459-69. PubMed ID: 21344976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival of Swedish glioblastoma patients treated according to Stupp.
    Bruhn H; Strandéus M; Milos P; Hallbeck M; Vrethem M; Lind J
    Acta Neurol Scand; 2018 Oct; 138(4):332-337. PubMed ID: 29882211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
    Lam N; Chambers CR
    J Oncol Pharm Pract; 2012 Jun; 18(2):229-38. PubMed ID: 22065199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
    Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
    J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status quo--standard-of-care medical and radiation therapy for glioblastoma.
    Becker KP; Yu J
    Cancer J; 2012; 18(1):12-9. PubMed ID: 22290252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
    Chamberlain MC; Glantz MJ; Chalmers L; Van Horn A; Sloan AE
    J Neurooncol; 2007 Mar; 82(1):81-3. PubMed ID: 16944309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
    Peca C; Pacelli R; Elefante A; Del Basso De Caro ML; Vergara P; Mariniello G; Giamundo A; Maiuri F
    Clin Neurol Neurosurg; 2009 May; 111(4):331-4. PubMed ID: 19117668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis.
    Wang C; Zhu N; Wang L; An Z
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C196-201. PubMed ID: 26506875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
    Illic R; Somma T; Savic D; Frio F; Milicevic M; Solari D; Nikitovic M; Lavrnic S; Raicevic S; Milosevic S; Cavallo LM; Cappabianca P; Grujicic D
    World Neurosurg; 2017 Aug; 104():581-588. PubMed ID: 28522381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
    Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
    Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.